Example: Heart Attack

Clinical Trials on Myeloproliferative Disorders

Total 1724 results

NCT04562389

Not yet recruiting

A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis

Conditions: Myelofibrosis
NCT04562870

Not yet recruiting

A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis

Conditions: Myelofibrosis
NCT04550442

Recruiting

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Conditions: Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome; Therapy-Related Myelodysplastic Syndrome
NCT04551053

Not yet recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Conditions: Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis
NCT04551066

Not yet recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

Conditions: Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis
NCT04543279

Not yet recruiting

Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia

Conditions: Myelofibrosis
NCT04539678

Recruiting

SYTHROM Cohort, Myeloproliferative Neoplasia With Normal CBC and Thrombotic Complications

Conditions: Thrombotic Patients; Diagnosis of Myeloproliferative Neoplasia; Impact of Treatment With Cytoreducing Agent
NCT04526795

Not yet recruiting

Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

Conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent Acute Biphenotypic Leukemia; Recurrent Acute Lymphoblastic Leukemia; Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Recurrent T-Cell Prolymphocytic Leukemia; Refractory Acute Biphenotypic Leukemia; Refractory Acute Lymphoblastic Leukemia; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Refractory T-Cell Prolymphocytic Leukemia
NCT04527666

Not yet recruiting

Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Conditions: Gastroesophageal Varices; JAK2 Mutation; Myeloproliferative Neoplasm
NCT04525768

Not yet recruiting

Gastroesophageal Varices in Cavernoma

Conditions: Gastroesophageal Varices; Myeloproliferative Neoplasm; Portal Caver Cavernoma; Portal Hypertension
NCT04522895

Recruiting

IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT

Conditions: Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; IDH2 Gene Mutation; IDH2 R172; IDH2 R140
NCT04518644

Available

Nilotinib, for Patients With CML-CP, CML-AP, or CML-BC

Conditions: Chronic Myelogenous Leukemia (CML)
NCT04517851

Not yet recruiting

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Conditions: Myelofibrosis Transformation in Essential Thrombocythemia; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis
NCT04509700

Recruiting

Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

Conditions: B-Cell Malignancies
NCT04493138

Recruiting

Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations

Conditions: Chronic Myelomonocytic Leukemia; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Recurrent Myeloproliferative Neoplasm
NCT04493164

Not yet recruiting

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Conditions: Acute Myeloid Leukemia With Gene Mutations; Myelodysplastic Syndrome; Myeloproliferative Neoplasm; Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia
NCT04487106

Recruiting

Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome

Conditions: Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Myelodysplastic Syndrome
NCT04485260

Not yet recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Conditions: Myelofibrosis
NCT04480086

Not yet recruiting

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Conditions: Myelofibrosis (MF)
NCT04473911

Recruiting

Haplo Peripheral Blood Sct In GVHD Prevention

Conditions: GVHD; AML; ALL; MDS; MPN; CMML; Hodgkin Lymphoma; Non Hodgkin Lymphoma; Blood Stem Cell Transplant Failure; Graft Vs Host Disease; Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorder; Chronic Myelomonocytic Leukemia; Chemosensitive Hodgkin Lymphoma
NCT04472598

Recruiting

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

Conditions: Myelofibrosis (MF)
NCT04468984

Recruiting

Safety, Efficacy, and Assessment of Change in Spleen Volume Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet in Adult Participants With Relapsed/Refractory Myelofibrosis

Conditions: Myelofibrosis (MF)
NCT04464889

Recruiting

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Conditions: Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders; Chronic Myeloid Leukemia; Myelofibrosis; Multiple Myeloma; Malignant Lymphoma
NCT04455841

Not yet recruiting

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Conditions: Anemia; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis
NCT04454658

Recruiting

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Conditions: Myelofibrosis (MF)
NCT04451200

Not yet recruiting

SEQUENTIAL AND PERSONALIZED BUSULFAN ADMINISTRATION BY PHARMACOKINETICS PATIENTS WITH MALIGNANT HEMOPATHIA

Conditions: Acute Leukemia; Mielodysplasic Syndrome; Myeloproliferative Neoplasm
NCT04446650

Not yet recruiting

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Conditions: Primary Myelofibrosis
NCT04424147

Enrolling by invitation

Efficacy and Safety of HVA Regimens as Salvage Treatment in rrAML

Conditions: Refractory Acute Myeloid Leukemia; Relapsed Acute Erythroid Leukemia; Salvage Treatment; HVA Regimen
NCT04416438

Recruiting

COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias

Conditions: Myeloproliferative Neoplasm; COVID-19 Infection
NCT04409639

Not yet recruiting

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

Conditions: Chronic Myelomonocytic Leukemia (CMML)
NCT04384692

Recruiting

Ruxolitinib for the Treatment of Graft Versus Host Disease Following Stem Cell Transplant in Patients With Primary and Secondary Myelofibrosis

Conditions: Primary Myelofibrosis; Secondary Myelofibrosis
NCT04384848

Recruiting

The EMPATHY Pilot Study

Conditions: Leukemia, Chronic Myeloid; Cancer
NCT04385160

Recruiting

Myeloproliferative Neoplasms (MPN) and COVID-19

Conditions: Myeloproliferative Neoplasm; COVID
NCT04378855

Not yet recruiting

Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).

Conditions: Myeloproliferative Neoplasm
NCT04375631

Recruiting

CLAG-M Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Conditions: Recurrent Acute Myeloid Leukemia; Recurrent Chronic Myelomonocytic Leukemia; Recurrent Myelodysplastic Syndrome; Refractory Acute Myeloid Leukemia; Refractory Chronic Myelomonocytic Leukemia; Refractory Mixed Phenotype Acute Leukemia; Refractory Myelodysplastic Syndrome; Refractory Acute Leukemia of Ambiguous Lineage; Refractory Acute Undifferentiated Leukemia
NCT04372433

Recruiting

IO-202 as Monotherapy in Patients in AML and CMML

Conditions: AML M5; AML M4; AML, Nos; Acute Myelogenous Leukemia in Relapse; Myelomonocytic Leukemia, Chronic
NCT04370301

Not yet recruiting

Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis

Conditions: Primary Myelofibrosis; Secondary Myelofibrosis
NCT04360005

Available

Managed Access Program (MAP)* to Provide Access to Asciminibfor Patients With CML in Chronic Phase

Conditions: Chronic Myeloid Leukemia
NCT04354727

Not yet recruiting

A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy

Conditions: Myelofibrosis
NCT04339101

Recruiting

Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation

Conditions: Acute Leukemia; Hematologic and Lymphocytic Disorder; Myelodysplastic Syndrome; Primary Myelofibrosis; Secondary Myelofibrosis
NCT04339400

Recruiting

A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms

Conditions: Myeloproliferative Neoplasms
NCT04312607

Not yet recruiting

Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm

Conditions: Myeloproliferative Neoplasm
NCT04285086

Recruiting

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Conditions: Essential Thrombocythemia
NCT04283526

Not yet recruiting

Study of Select Combinations in Adults With Myelofibrosis

Conditions: Primary Myelofibrosis; Myelofibrosis; PMF; Post-Essential Thrombocythemia Myelofibrosis; Post-Polycythemia Vera Myelofibrosis
NCT04281498

Not yet recruiting

Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation

Conditions: Accelerated/Blast-phase Myeloproliferative Neoplasm; Chronic-phase Myelofibrosis; IDH2 Mutation
NCT04282174

Not yet recruiting

CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies

Conditions: Hematologic Diseases; Hematologic Malignancy; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Myelogenous Leukemia; Chronic Lymphocytic Leukemia
NCT04282187

Recruiting

Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Conditions: Acute Myeloid Leukemia; Essential Thrombocythemia; Myelodysplastic Syndrome; Myelodysplastic/Myeloproliferative Neoplasm; Myeloproliferative Neoplasm; Myeloproliferative Neoplasm, Unclassifiable; Polycythemia Vera; Primary Myelofibrosis; Secondary Myelofibrosis
NCT04282343

Not yet recruiting

DISCO Application for the Improvement of Financial Outcomes in Patients With Hematologic Cancer

Conditions: Chronic Lymphocytic Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Plasma Cell Myeloma
NCT04282421

Completed

Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France

Conditions: Myelofibrosis
NCT04279847

Recruiting

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis

Conditions: Relapsed or Refractory Primary Myelofibrosis; Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)

COOKIE SETTINGS

Clinical Trials on Myeloproliferative Disorders